The Patent Finder

Cormorant Pharmaceuticals AB

Also on record
Records under this name other than patents Cormorant Pharmaceuticals AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 7 of 7 · Back to Cormorant Pharmaceuticals AB

PatentTitleStatus Expires Confidence
US 10,066,012Human Monoclonal Antibodies Against Interleukin 8 (IL-8)
Term ended
Ended no later than Aug 28, 2024 · Medium confidence
Term endedEnded no later than Aug 28, 2024Medium confidence
US 7,282,568Human Monoclonal Antibodies Against Interleukin 8 (IL-8)
Term ended
Term ended May 13, 2024 · High confidence
Term endedTerm ended May 13, 2024High confidence
US 7,622,559Human Monoclonal Antibodies Against Interleukin 8 (IL-8)
Term ended
Ended no later than Dec 16, 2023 · Medium confidence
Term endedEnded no later than Dec 16, 2023Medium confidence
US 8,105,588Human Monoclonal Antibodies Against Interleukin 8 (IL-8)
Term ended
Term ended Dec 16, 2023 · High confidence
Term endedTerm ended Dec 16, 2023High confidence
US 8,603,469Methods of Treating Cancer with Human Monoclonal Antibodies Against Interleukin 8
Term ended
Term ended Dec 16, 2023 · High confidence
Term endedTerm ended Dec 16, 2023High confidence
US 10,253,093Human Monoclonal Antibodies Against Interleukin 8 (IL-8)
Term ended
Term ended Dec 16, 2023 · Medium confidence
Term endedTerm ended Dec 16, 2023Medium confidence
US 11,339,215Methods of Treating Cancer with Human Monoclonal Antibodies Against Interleukin 8 (IL-8)
Term ended
Term ended Dec 16, 2023 · High confidence
Term endedTerm ended Dec 16, 2023High confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited